ERBB2 and breast carcinoma: In clinical therapeutics, Trastuzumab, a humanized monoclonal antibody targeting cells overexpressed ErbB2 (HER2), is administered mainly in HER2-positive breast cancer, offering survival advantage in these patients [74].